Published in Br J Pharmacol on June 05, 2006
Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract (2008) 2.66
Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat Clin Pract Urol (2007) 2.06
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res (2011) 1.89
Persistence of antimuscarinic drug use. Eur J Clin Pharmacol (2008) 1.80
Central role of the BK channel in urinary bladder smooth muscle physiology and pathophysiology. Am J Physiol Regul Integr Comp Physiol (2014) 1.76
Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. ACS Chem Neurosci (2010) 1.52
Spontaneous release of acetylcholine from autonomic nerves in the bladder. Br J Pharmacol (2009) 1.47
Muscarinic receptors and ligands in cancer. Am J Physiol Cell Physiol (2008) 1.42
Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia. Neuropsychopharmacology (2011) 1.42
Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol (2007) 1.37
Activation of muscarinic receptors in rat bladder sensory pathways alters reflex bladder activity. J Neurosci (2008) 1.26
The antipsychotic potential of muscarinic allosteric modulation. Drug News Perspect (2010) 1.15
Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. Dig Dis Sci (2010) 1.05
A phase II dose-ranging study of mirabegron in patients with overactive bladder. Int Urogynecol J (2013) 0.98
Mechanotransduction and chemosensitivity of two major classes of bladder afferents with endings in the vicinity to the urothelium. J Physiol (2009) 0.97
Clinical features of organophosphate poisoning: A review of different classification systems and approaches. Indian J Crit Care Med (2014) 0.96
Synthesis, trafficking, and localization of muscarinic acetylcholine receptors. Pharmacol Ther (2008) 0.96
Distinct muscarinic acetylcholine receptor subtypes contribute to stability and growth, but not compensatory plasticity, of neuromuscular synapses. J Neurosci (2009) 0.96
Bladder dysfunction in diabetes mellitus. Front Pharmacol (2010) 0.90
Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease. Drug Discov Today (2013) 0.90
Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis (2012) 0.89
Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071. Bioorg Med Chem Lett (2011) 0.89
Signalling to contractile proteins by muscarinic and purinergic pathways in neurally stimulated bladder smooth muscle. J Physiol (2012) 0.88
Control of striatal signaling by g protein regulators. Front Neuroanat (2011) 0.87
Bladder and bowel dysfunction in Parkinson's disease. J Neural Transm (Vienna) (2008) 0.87
Expression of muscarinic receptors in human and mouse sclera and their role in the regulation of scleral fibroblasts proliferation. Mol Vis (2009) 0.87
In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol (2009) 0.87
Functional, morphological and molecular characterization of bladder dysfunction in streptozotocin-induced diabetic mice: evidence of a role for L-type voltage-operated Ca2+ channels. Br J Pharmacol (2011) 0.87
Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity. Int Urogynecol J (2011) 0.87
Phenotype pharmacology of lower urinary tract α(1)-adrenoceptors. Br J Pharmacol (2012) 0.86
Muscarinic receptor signaling in colon cancer. Cancers (Basel) (2011) 0.86
Alteration in TRPV1 and Muscarinic (M3) receptor expression and function in idiopathic overactive bladder urothelial cells. Acta Physiol (Oxf) (2012) 0.86
Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study. Br J Clin Pharmacol (2010) 0.86
Functional significance of muscarinic receptor expression within the proximal and distal rat vagina. Am J Physiol Regul Integr Comp Physiol (2009) 0.86
Rationale for the use of anticholinergic agents in overactive bladder with regard to central nervous system and cardiovascular system side effects. Korean J Urol (2013) 0.86
Long-term nitric oxide deficiency causes muscarinic supersensitivity and reduces beta(3)-adrenoceptor-mediated relaxation, causing rat detrusor overactivity. Br J Pharmacol (2008) 0.84
Bladder, bowel, and sexual dysfunction in Parkinson's disease. Parkinsons Dis (2011) 0.84
Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal women. Clin Drug Investig (2012) 0.84
In vivo bladder selectivity of imidafenacin, a novel antimuscarinic agent, assessed by using an effectiveness index for bladder capacity in rats. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.83
Does phospholipase C mediate muscarinic receptor-induced rat urinary bladder contraction? J Pharmacol Exp Ther (2007) 0.83
Effects of stimulation of muscarinic receptors on bladder afferent nerves in the in vitro bladder-pelvic afferent nerve preparation of the rat. Brain Res (2010) 0.83
Similarities and differences in the autonomic control of airway and urinary bladder smooth muscle. Naunyn Schmiedebergs Arch Pharmacol (2008) 0.82
The effect of hypercholesterolemia on carbachol-induced contractions of the detrusor smooth muscle in rats: increased role of L-type Ca2+ channels. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.82
Does anticholinergic medication have a role in treating men with overactive bladder and benign prostatic hyperplasia? Naunyn Schmiedebergs Arch Pharmacol (2008) 0.81
Anticholinergic effects of cis- and trans-isomers of two metabolites of propiverine. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.81
Age-dependent contribution of Rho kinase in carbachol-induced contraction of human detrusor smooth muscle in vitro. Acta Pharmacol Sin (2013) 0.80
Urothelium muscarinic activation phosphorylates CBS(Ser227) via cGMP/PKG pathway causing human bladder relaxation through H2S production. Sci Rep (2016) 0.80
Simultaneous optical and electrical in vivo analysis of the enteric nervous system. Nat Commun (2016) 0.79
A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trials. Drug Healthc Patient Saf (2012) 0.79
Comparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humans. Am J Physiol Gastrointest Liver Physiol (2010) 0.79
Contribution of the M3 muscarinic receptors to the vasodilator response to acetylcholine in the human forearm vascular bed. Br J Clin Pharmacol (2008) 0.78
Update on the management of overactive bladder: patient considerations and adherence. Open Access J Urol (2010) 0.78
Factors predicting use of laxatives in outpatients stabilized on clozapine. Ther Adv Psychopharmacol (2015) 0.78
Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis. Int J Mol Sci (2016) 0.78
Spatiotemporal Mapping Techniques Show Clozapine Impairs Neurogenic and Myogenic Patterns of Activity in the Colon of the Rabbit in a Dose-Dependent Manner. Front Pharmacol (2017) 0.78
Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice. PLoS One (2012) 0.77
Carbachol-induced signaling through Thr696-phosphorylation of myosin phosphatase-targeting subunit 1 (MYPT1) in rat bladder smooth muscle cells. Int Urol Nephrol (2016) 0.76
Protective Role of Quercetin in Cadmium-Induced Cholinergic Dysfunctions in Rat Brain by Modulating Mitochondrial Integrity and MAP Kinase Signaling. Mol Neurobiol (2016) 0.76
Big-conductance Ca(2+)-activated K(+) channels in physiological and pathophysiological urinary bladder smooth muscle cells. Channels (Austin) (2016) 0.75
A novel luminescence-based method for the detection of functionally active antibodies to muscarinic acetylcholine receptors of the M3 type (mAchR3) in patients' sera. Clin Exp Immunol (2014) 0.75
Impact of mirabegron extended-release on the treatment of overactive bladder with urge urinary incontinence, urgency, and frequency. Res Rep Urol (2013) 0.75
Diabetic plasticity of non-adrenergic non-cholinergic and P2X-mediated rat bladder contractions. Brain Res Bull (2013) 0.75
Overactive bladder - 18 years - Part II. Int Braz J Urol (2016) 0.75
Pharmacologic characteristics of bladder micturition function in anesthetized mice. Comp Med (2010) 0.75
Evaluation and management of overactive bladder: strategies for optimizing care. Res Rep Urol (2016) 0.75
Tolterodine Tartrate Proniosomal Gel Transdermal Delivery for Overactive Bladder. Pharmaceutics (2016) 0.75
Comparison of solifenacin and fesoterodine in treatment of overactive bladder. Saudi Med J (2015) 0.75
The Functional Haplotypes of CHRM3 Modulate mRNA Expression and Associate with Bladder Cancer among a Chinese Han Population in Kaohsiung City. Biomed Res Int (2016) 0.75
Impact of anticholinergic load on bladder function. Int Urogynecol J (2014) 0.75
Imidafenacin has no influence on learning in nucleus basalis of Meynert-lesioned rats. Naunyn Schmiedebergs Arch Pharmacol (2013) 0.75
Muscarinic receptor expression and receptor-mediated detrusor contraction: comparison of juvenile and adult porcine tissue. Pflugers Arch (2007) 0.75
Older People's Preferences for Side Effects Associated with Antimuscarinic Treatments of Overactive Bladder: A Discrete-Choice Experiment. Drugs Aging (2017) 0.75
Dry eye findings worsen with anticholinergic therapy in patients with urge incontinence. Int Urogynecol J (2015) 0.75
Comparative functional selectivity of imidafenacin and propiverine, antimuscarinic agents, for the urinary bladder over colon in conscious rats. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.75
The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn (2002) 22.80
Drug-induced prolongation of the QT interval. N Engl J Med (2004) 10.96
A systematic review of the associations between dose regimens and medication compliance. Clin Ther (2001) 9.23
The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis (2004) 5.49
International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev (1998) 5.34
Muscarinic receptors--characterization, coupling and function. Pharmacol Ther (1993) 4.36
Muscarinic receptor subtypes. Annu Rev Pharmacol Toxicol (1990) 3.64
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc (2003) 2.75
Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann Neurol (2003) 2.61
Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry (2003) 2.60
Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature (2001) 2.39
Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci (2003) 2.35
Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol (1997) 2.35
A neurologic basis for the overactive bladder. Urology (1997) 2.23
Muscarinic receptor antagonists in the treatment of overactive bladder. Urology (2000) 2.23
Functional role of M2 and M3 muscarinic receptors in the urinary bladder of rats in vitro and in vivo. Br J Pharmacol (1997) 2.18
Pronounced pharmacologic deficits in M2 muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A (1999) 2.16
Antimuscarinics for treatment of overactive bladder. Lancet Neurol (2004) 2.11
The impact of reducing dose frequency on health outcomes. Clin Ther (2003) 2.01
Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther (1995) 1.96
Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc Natl Acad Sci U S A (2000) 1.96
Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology (2001) 1.92
Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A (2001) 1.87
The pharmacokinetics of oxybutynin in man. Eur J Clin Pharmacol (1988) 1.83
Feline interstitial cystitis results in mechanical hypersensitivity and altered ATP release from bladder urothelium. Am J Physiol Renal Physiol (2003) 1.73
Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology (2004) 1.67
Muscarinic receptors in the mammalian heart. Pharmacol Res (2001) 1.64
Principles of saliva secretion. Ann N Y Acad Sci (1993) 1.59
M2 muscarinic receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol (1998) 1.55
Muscarinic receptors of the urinary bladder: detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol (2002) 1.55
M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. J Neurosci (2004) 1.53
Mice lacking M2 and M3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable. J Neurosci (2002) 1.51
Antimuscarinics and the overactive detrusor--which is the main mechanism of action? Eur Urol (2003) 1.50
M(3) receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn Schmiedebergs Arch Pharmacol (2002) 1.49
Anticholinergic effects of medication in elderly patients. J Clin Psychiatry (2001) 1.45
Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group. J Urol (1999) 1.44
Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc (2003) 1.43
Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur J Neurosci (2003) 1.41
M(2) and M(4) receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle in vitro. J Pharmacol Exp Ther (2000) 1.40
Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog Brain Res (2004) 1.35
Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells. Brain Res (2001) 1.34
Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin. J Clin Pharmacol (1999) 1.33
Muscarinic receptor subtypes modulating smooth muscle contractility in the urinary bladder. Life Sci (1999) 1.33
The autonomous bladder: a view of the origin of bladder overactivity and sensory urge. BJU Int (2004) 1.30
Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2. Am J Physiol Regul Integr Comp Physiol (2003) 1.30
Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol (2004) 1.26
Cholinergic stimulation of salivary secretion studied with M1 and M3 muscarinic receptor single- and double-knockout mice. Mol Pharmacol (2004) 1.25
Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc (1998) 1.23
The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol (2002) 1.23
M(3)-receptor knockout mice: muscarinic receptor function in atria, stomach fundus, urinary bladder, and trachea. Am J Physiol Regul Integr Comp Physiol (2002) 1.21
Cholinergic agonists transactivate EGFR and stimulate MAPK to induce goblet cell secretion. Am J Physiol Cell Physiol (2002) 1.19
Drug delivery to the retina: challenges and opportunities. Expert Opin Biol Ther (2003) 1.18
The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol Regul Integr Comp Physiol (2004) 1.18
An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int (2005) 1.15
Determinants of passive drug entry into the central nervous system. Cell Mol Neurobiol (2000) 1.14
The M2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder. J Pharmacol Exp Ther (2004) 1.14
M1 muscarinic agonists can modulate some of the hallmarks in Alzheimer's disease: implications in future therapy. J Mol Neurosci (2003) 1.10
Agonist- and nerve-induced phasic activity in the isolated whole bladder of the guinea pig: evidence for two types of bladder activity. Exp Physiol (2003) 1.08
Muscarinic receptor subtypes in human iris-ciliary body measured by immunoprecipitation. Invest Ophthalmol Vis Sci (1997) 1.07
The pharmacological treatment of urinary incontinence. BJU Int (1999) 1.06
M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol (2002) 1.05
Assessment of cognitive function of the elderly population: effects of darifenacin. J Urol (2005) 1.04
Current concepts in the treatment of disorders of micturition. Drugs (1988) 1.04
Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists. Eur J Pharmacol (1998) 1.03
Expression of multiple subtypes of muscarinic receptors and cellular distribution in the human heart. Mol Pharmacol (2001) 1.03
Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice. Mol Psychiatry (2003) 1.03
QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder. J Clin Pharmacol (2005) 1.02
Oxybutynin and cognitive dysfunction. BMJ (1997) 1.02
Disruption of the blood-brain barrier and neuronal cell death in cingulate cortex, dentate gyrus, thalamus, and hypothalamus in a rat model of Gulf-War syndrome. Neurobiol Dis (2002) 1.02
Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis and treatment. Pharmacol Ther (1997) 1.01
Functional M3 muscarinic acetylcholine receptors in mammalian hearts. Br J Pharmacol (2004) 1.01
Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol (1994) 1.01
Control of bladder function by peripheral nerves: avenues for novel drug targets. Urology (2004) 1.01
Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier. Med Sci Monit (2001) 1.00
Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder. Life Sci (1999) 1.00
Muscarinic receptors and gastrointestinal tract smooth muscle function. Life Sci (2001) 0.98
Cholinergic and nitrergic regulation of in vivo giant migrating contractions in rat colon. Am J Physiol Gastrointest Liver Physiol (2002) 0.98
M1 muscarinic receptor-induced facilitation of ACh and noradrenaline release in the rat bladder is mediated by protein kinase C. J Physiol (1996) 0.97
Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder. World J Urol (2005) 0.97
Muscarinic (M) receptors in coronary circulation: gene-targeted mice define the role of M2 and M3 receptors in response to acetylcholine. Arterioscler Thromb Vasc Biol (2004) 0.97
Evidence for a preferential involvement of M1 muscarinic receptors in representational memory. Neurosci Lett (1990) 0.96
Selective inactivation of muscarinic M2 and M3 receptors in guinea-pig ileum and atria in vitro. Br J Pharmacol (1993) 0.96
Muscarinic receptor subtypes in human and rat colon smooth muscle. Biochem Pharmacol (1992) 0.95
Clinical pharmacology of terodiline. Scand J Urol Nephrol Suppl (1984) 0.94
A muscarinic receptor different from the M1, M2, M3 and M4 subtypes mediates the contraction of the rabbit iris sphincter. Naunyn Schmiedebergs Arch Pharmacol (1992) 0.93
Treatment of overactive bladder: long-term tolerability and efficacy of tolterodine. World J Urol (2001) 0.93
Cystometric findings in mice lacking muscarinic M2 or M3 receptors. J Urol (2004) 0.93
Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol (2004) 0.92
Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disord (2003) 0.92
Multiple dose pharmacokinetics of a new once daily extended release tolterodine formulation versus immediate release tolterodine. Clin Pharmacokinet (2001) 0.92
Muscarinic M3 receptor subtype gene expression in the human heart. Cell Mol Life Sci (2000) 0.92
Characterization of muscarinic receptors in human lens cells by pharmacologic and molecular techniques. Invest Ophthalmol Vis Sci (2000) 0.91
Pharmacodynamic effects of darifenacin, a muscarinic M selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU Int (2005) 0.91
Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol (2003) 0.91
Contractile response of the isolated trabecular meshwork and ciliary muscle to cholinergic and adrenergic agents. Ger J Ophthalmol (1996) 0.90
Change in muscarinic modulation of transmitter release in the rat urinary bladder after spinal cord injury. Neurochem Int (2003) 0.90
Heterogeneity of release-inhibiting muscarinic autoreceptors in heart atria and urinary bladder: a study with M(2)- and M(4)-receptor-deficient mice. Naunyn Schmiedebergs Arch Pharmacol (2001) 0.90
Characterization of muscarinic receptors in cultured human iris sphincter and ciliary smooth muscle cells. Exp Eye Res (1993) 0.89
Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers. Clin Drug Investig (2003) 0.89
Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med (2011) 5.30
Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) (2006) 3.68
An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol (2003) 3.21
Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence. Pharmacol Rev (2004) 3.08
Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol (2010) 2.68
The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int (2009) 2.63
Incidence of benign pathologic findings at partial nephrectomy for solitary renal mass presumed to be renal cell carcinoma on preoperative imaging. Urology (2006) 2.59
Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol (2008) 2.57
Urothelial signaling. Physiol Rev (2013) 2.56
Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci (2003) 2.35
Neuronal activity rapidly induces transcription of the CREB-regulated microRNA-132, in vivo. Hippocampus (2010) 2.30
Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder. Eur Urol (2007) 2.21
Cholinergic modulation of Kir2 channels selectively elevates dendritic excitability in striatopallidal neurons. Nat Neurosci (2007) 2.15
EAU guidelines on urinary incontinence. Eur Urol (2010) 2.10
Minimal tumor volume may provide additional prognostic information in good performance patients after radical prostatectomy. Urology (2007) 2.09
The European Association of Urology (EAU) guidelines methodology: a critical evaluation. Eur Urol (2008) 2.04
The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int (2009) 2.00
Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol (2012) 1.95
Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol (2013) 1.83
Muscarinic receptor antagonists for overactive bladder. BJU Int (2007) 1.81
Summary of the recommendations on sexual dysfunctions in men. J Sex Med (2004) 1.78
A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol (2009) 1.76
Partial outlet obstruction enhances modular autonomous activity in the isolated rat bladder. J Urol (2003) 1.75
Repeat prostate biopsy and the incremental risk of clinically insignificant prostate cancer. Urology (2011) 1.70
Systematic review of combination drug therapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.65
Preoperative parameters, including percent positive biopsy, in predicting seminal vesicle involvement in patients with prostate cancer. J Urol (2006) 1.64
Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol (2008) 1.62
Cholinergic suppression of KCNQ channel currents enhances excitability of striatal medium spiny neurons. J Neurosci (2005) 1.61
OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium. BJU Int (2013) 1.61
Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol (2006) 1.61
Increased bladder activity is associated with elevated oxidative stress markers and proinflammatory cytokines in a rat model of atherosclerosis-induced chronic bladder ischemia. Neurourol Urodyn (2011) 1.60
Bladder dysfunction in a new mutant mouse model with increased superoxide--lack of nitric oxide? J Urol (2010) 1.58
Recent advances in understanding the biology of diabetes-associated bladder complications and novel therapy. BJU Int (2005) 1.56
Nocturia Think Tank: focus on nocturnal polyuria: ICI-RS 2011. Neurourol Urodyn (2012) 1.56
Downregulation of cGMP-dependent protein kinase-1 activity in the corpus cavernosum smooth muscle of diabetic rabbits. Am J Physiol Regul Integr Comp Physiol (2004) 1.55
A randomized controlled trial of intravesical bacillus calmette-guerin for treatment refractory interstitial cystitis. J Urol (2005) 1.54
Future direction in pharmacotherapy for non-neurogenic male lower urinary tract symptoms. Eur Urol (2013) 1.54
Urine derived cells are a potential source for urological tissue reconstruction. J Urol (2008) 1.54
Impact on renal function of percutaneous thermal ablation of renal masses in patients with preexisting chronic kidney disease. J Vasc Interv Radiol (2011) 1.54
The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology (2006) 1.54
The New England Research Institutes, Inc. (NERI) Nocturia Advisory Conference 2012: focus on outcomes of therapy. BJU Int (2013) 1.52
Urodynamic studies in adults: AUA/SUFU guideline. J Urol (2012) 1.51
Comparison of the efficacy, safety, and tolerability of propiverine and oxybutynin for the treatment of overactive bladder syndrome. Int J Urol (2006) 1.50
Identification of clinically significant prostate cancer by prostate-specific antigen screening. Arch Intern Med (2004) 1.46
Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol (2007) 1.46
The inhibitory role of acetylcholine and muscarinic receptors in bladder afferent activity. Eur Urol (2010) 1.46
Smooth-muscle-specific gene transfer with the human maxi-k channel improves erectile function and enhances sexual behavior in atherosclerotic cynomolgus monkeys. Eur Urol (2008) 1.46
Mechanisms of action of botulinum neurotoxins, β3-adrenergic receptor agonists, and PDE5 inhibitors in modulating detrusor function in overactive bladders: ICI-RS 2011. Neurourol Urodyn (2012) 1.46
Botulinum toxin for spastic GI disorders: a systematic review. Gastrointest Endosc (2003) 1.45
Transient receptor potential vanilloid 1 mediates hyperalgesia and is up-regulated in rats with chronic pancreatitis. Gastroenterology (2007) 1.44
Effect of melatonin on chronic bladder-ischaemia-associated changes in rat bladder function. BJU Int (2013) 1.44
Presence of phosphodiesterase type 5 in the spinal cord and its involvement in bladder outflow obstruction related bladder overactivity. J Urol (2013) 1.43
Design and validation of a new screening instrument for lower urinary tract dysfunction: the bladder control self-assessment questionnaire (B-SAQ). Eur Urol (2006) 1.43
Enucleation of renal cell carcinoma with ablation of the tumour base. BJU Int (2008) 1.41
Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity. Eur J Neurosci (2003) 1.41
Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats. J Urol (2004) 1.41
The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int (2009) 1.40
Localization and function of cannabinoid receptors in the corpus cavernosum: basis for modulation of nitric oxide synthase nerve activity. Eur Urol (2009) 1.40
Protective effect of a β3-adrenoceptor agonist on bladder function in a rat model of chronic bladder ischemia. Eur Urol (2013) 1.39
Association between utility and treatment among patients with prostate cancer. Qual Life Res (2010) 1.39
Images in clinical medicine. Eosinophilic esophagitis. N Engl J Med (2007) 1.38
Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci (2005) 1.35
Diabetes induces sex-dependent changes in neuronal nitric oxide synthase dimerization and function in the rat gastric antrum. Am J Physiol Gastrointest Liver Physiol (2007) 1.35
Neural stem cell transplantation in the stomach rescues gastric function in neuronal nitric oxide synthase-deficient mice. Gastroenterology (2005) 1.29
Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am J Physiol Renal Physiol (2003) 1.27
Simultaneous registration of intraabdominal and intravesical pressures during cystometry in conscious rats--effects of bladder outlet obstruction and intravesical PGE2. Neurourol Urodyn (2008) 1.26
Bladder afferent signaling: recent findings. J Urol (2010) 1.25
Quantitative analysis of muscarinic acetylcholine receptor homo- and heterodimerization in live cells: regulation of receptor down-regulation by heterodimerization. J Biol Chem (2005) 1.24
Enhanced excitability and suppression of A-type K+ current of pancreas-specific afferent neurons in a rat model of chronic pancreatitis. Am J Physiol Gastrointest Liver Physiol (2006) 1.23
Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur Urol (2011) 1.23
Human bladder as a novel target for vitamin D receptor ligands. J Clin Endocrinol Metab (2004) 1.22
Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging (2004) 1.22
Characterization of urine-derived stem cells obtained from upper urinary tract for use in cell-based urological tissue engineering. Tissue Eng Part A (2011) 1.21
CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer. Cancer Res (2004) 1.21
Detrusor overactivity is associated with downregulation of large-conductance calcium- and voltage-activated potassium channel protein. Am J Physiol Renal Physiol (2010) 1.21
A mutation in the inner mitochondrial membrane peptidase 2-like gene (Immp2l) affects mitochondrial function and impairs fertility in mice. Biol Reprod (2007) 1.20
Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol (2009) 1.19
Increased connexin43-mediated intercellular communication in a rat model of bladder overactivity in vivo. Am J Physiol Regul Integr Comp Physiol (2003) 1.19
Cisplatin-induced hair cell death requires STAT1 and is attenuated by epigallocatechin gallate. J Neurosci (2009) 1.18
Characteristics of patients presenting with LUTS/BPH in six European countries. Eur Urol (2006) 1.17
Chronic, intermittent exposure to chlorpyrifos in rats: protracted effects on axonal transport, neurotrophin receptors, cholinergic markers, and information processing. J Pharmacol Exp Ther (2007) 1.17
A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol (2008) 1.16
Intravesical adenosine triphosphate stimulates the micturition reflex in awake, freely moving rats. J Urol (2002) 1.15
Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int (2006) 1.15
Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int (2008) 1.15
Origins and patterns of spontaneous and drug-induced canine gastric myoelectrical dysrhythmia. Dig Dis Sci (2003) 1.13
Increased basal phosphorylation of detrusor smooth muscle myosin in alloxan-induced diabetic rabbit is mediated by upregulation of Rho-kinase beta and CPI-17. Am J Physiol Renal Physiol (2005) 1.12
Diabetes induced decrease in detrusor smooth muscle force is associated with oxidative stress and overactivity of aldose reductase. J Urol (2005) 1.12
Endorectal T2-weighted MRI does not differentiate between favorable and adverse pathologic features in men with prostate cancer who would qualify for active surveillance. Urol Oncol (2012) 1.12
Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology (2006) 1.12
The role of the rhabdosphincter in female rat voiding. BJU Int (2004) 1.11
Management of lower urinary tract symptoms in men: summary of NICE guidance. BMJ (2010) 1.09
Detrusor responses to prostaglandin E2 and bladder outlet obstruction in wild-type and Ep1 receptor knockout mice. J Urol (2004) 1.09
Nerve growth factor modulates TRPV1 expression and function and mediates pain in chronic pancreatitis. Gastroenterology (2011) 1.08
Benign prostatic hyperplasia in primary care: what you need to know. J Urol (2006) 1.08
Chlorpyrifos, chlorpyrifos-oxon, and diisopropylfluorophosphate inhibit kinesin-dependent microtubule motility. Toxicol Appl Pharmacol (2006) 1.07
Experimental colitis triggers the release of substance P and calcitonin gene-related peptide in the urinary bladder via TRPV1 signaling pathways. Exp Neurol (2010) 1.07
Diagnosis and reconstruction of the dorsal or circumferential urethral diverticulum. J Urol (2003) 1.07
A review of adherence to drug therapy in patients with overactive bladder. BJU Int (2008) 1.06